AbbVie Inc.
ABBV
$185.58
-$2.51-1.33%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.10B | 14.46B | 14.46B | 12.31B | 14.30B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.10B | 14.46B | 14.46B | 12.31B | 14.30B |
| Cost of Revenue | 4.40B | 4.21B | 4.20B | 4.02B | 4.18B |
| Gross Profit | 10.71B | 10.25B | 10.26B | 8.29B | 10.12B |
| SG&A Expenses | 2.88B | 4.00B | 3.31B | 3.00B | 3.56B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -7.00M | -- | -- | -- | 169.00M |
| Total Operating Expenses | 9.57B | 10.28B | 9.46B | 8.83B | 9.83B |
| Operating Income | 5.54B | 4.18B | 5.00B | 3.48B | 4.47B |
| Income Before Tax | -2.27B | 2.08B | 2.15B | 1.76B | 1.21B |
| Income Tax Expenses | -2.25B | 520.00M | 773.00M | 383.00M | 388.00M |
| Earnings from Continuing Operations | -23.00M | 1.56B | 1.37B | 1.37B | 824.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00M | -3.00M | -3.00M | -3.00M | -2.00M |
| Net Income | -22.00M | 1.56B | 1.37B | 1.37B | 822.00M |
| EBIT | 5.54B | 4.18B | 5.00B | 3.48B | 4.47B |
| EBITDA | 7.64B | 6.26B | 7.13B | 5.56B | 6.55B |
| EPS Basic | -0.02 | 0.88 | 0.77 | 0.77 | 0.46 |
| Normalized Basic EPS | 1.76 | 1.33 | 1.62 | 1.07 | 1.45 |
| EPS Diluted | -0.02 | 0.88 | 0.77 | 0.77 | 0.46 |
| Normalized Diluted EPS | 1.76 | 1.33 | 1.62 | 1.07 | 1.45 |
| Average Basic Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Average Diluted Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B |
| Dividend Per Share | 1.64 | 1.55 | 1.55 | 1.55 | 1.55 |
| Payout Ratio | -12,509.09% | 176.23% | 200.73% | 202.48% | 319.46% |